The authors reported that ERBB2‐amplified tumors may benefit from anti‐HER2 therapy, and hypermutated tumors or tumors with high tumor mutational burden with MSI‐H or POLE mutation may benefit from anti‐PD‐1 therapy.10 Here, ERBB2 is linked to neoplasm.